Background and Aims: Dysphagia after stroke is common, especially in tracheotomised patients. In pilot trials, pharyngeal electrical stimulation (PES) reduced dysphagia after stroke. Method: Dysphagic tracheotomised post-stroke patients were randomised to receive three days of PES or sham. The primary outcome was readiness for decannulation 24-72 hours after treatment. Patients with persisting dysphagia were then offered open-label PES. Additional predefined outcomes were adverse events (AEs), readiness for decannulation after receiving open-label PES, and length-of-stay in hospital. The trial was registered as ISRCTN18137204. Results: The trial was stopped early for efficacy with 69 patients (PES 35, sham 34) randomised. PES was associated with more patients ready for decannulation then sham: 17 (48.6%) vs 3 (8.8%), odds ratio (OR) 7.00
Background and Aims: Vojta therapy is a type physiotherapy that is based on reflex-locomotion and was originally developed for newborns with central coordination or spastic movement disorders. We thought to transfer the concept to adult patients with acute stroke. Vojta therapy has been reported to activate trunk and the deep muscles of the spine to regulate trunk stability and increase spinal rotation force, thereby enhancing postural control. We hypothesize, that Vojta therapy improves postural control and motor function in patients with ischemic stroke (IS) or intracerebral hemorrhage (ICH). Method: We performed a randomized controlled, open-label, outcomeblinded trial. We included patients with imaging-confirmed IS or ICH, severe hemiparesis and randomly assigned them to Vojta therapy or conventional physiotherapy within 72 h after onset. Main exclusion criteria was restricted ability to communicate. Primary endpoint was the improvement of postural control measured by the trunk control test (TCT) on day 9 after admission. Results: Between December 02, 2015 and July 05, 2017 we screened 778 and included 40 patients. Median age was 75 (66-80) years, 50% were women. The median improvement on TCT within 9 days was 25,5 points (¼25,5%) (IQR 12,5-42,5) in the Vojta group and 0 (IQR 0-13) in the control group (p ¼ 0,001). Secondary endpoints supported this result and will be presented.
Background and Aims:
Optimal imaging selection criteria for thrombectomy is unknown. Method: In this prospective cohort study, consecutive anterior circulation LVOs up-to-24hours were enrolled, (1/16-2/18), at 9 centers. Patients received both NCCT and CTP with mismatch determination using RAPID software. Imaging selection modality was documented by treating physicians prior to thrombectomy. A blinded independent corelab adjudicated imaging profiles (Good CT ¼ASPECTS ! 6, Good CTP ¼ core-volume < 70 cc, mismatch-volume !10 cc and mismatch/ ratio >1.2). The primary outcome (90day-mRS ¼ 0-2) was compared between NCCT and CTP groups, and for different NCCT and CTP profiles. Results: Of 445 enrolled, 341 received thrombectomy, 13% had ICA occlusions, 62%M1, and 18%M2. Physicians reported NCCT as selection modality in 41%, CTP in 59%, good outcome rates were similar (NCCT ¼ 53.7% vs. CTP ¼ 54.2%, aOR ¼ 0.93, 95%CI ¼ 0.39-2.26, p ¼ 0.88). 86.7% had ASPECTS>6 and 88.8% had good perfusion profile (Table1) with comparable mRs ¼ 0-2 (55.9% versus 58%, aOR ¼ 2.37,95% CI ¼ 0.51-10.92, p ¼ 0.27). There was no interaction of imaging modality and outcome with time (0-6hrs versus 6-24hrs, p ¼ 0.97). 17.6% would have been excluded from thrombectomy based on NCCT or CTP only; 42% of them had good outcome. 52.2% of patients who were excluded by NCCT but qualified by CTP had mRS ¼ 0-2 after thrombectomy, and 27.8% of those excluded by CTP but were treated by NCCT had good outcome as compared to 27.3% and 0% of those with the same imaging profiles who did not receive thrombectomy. Thrombectomy did not confer good outcomes in patients with poor imaging profiles on both CT and CTP.
Background and Aims: Stroke increasingly affects people in low and middle-income countries (LMICs). Improvements in stroke care and outcomes have been reported in high income countries (HICs) but little is known about practice and outcomes in LMICs. Method: We studied practice variations (treatments used and access to services) among INTERSTROKE study stroke patients. We supplemented individual patient data with a questionnaire about healthcare and service facilities at each participating hospital. Using multivariate regression analyses to account for patient case-mix and service clustering, we estimated the association between services available, treatments given, and patient outcomes (death or dependency) at one month. Results: We obtained full information for 12,342 (92%) of 13,447 INTERSTROKE patients, from 108 hospitals in 28 countries; 2576 from 38 hospitals in 10 HICs and 9766 from 78 hospitals in 18 LMICs. LMIC patients more often (P < 0.0001) had severe strokes, intracerebral haemorrhage, poorer access to services, and lower use of investigations and treatments. Access to a stroke unit was associated (P < 0.0001) with improved use of investigations and treatments, access to other rehabilitation services, and improved survival without severe dependency (1.29; 1.14-1.44) which was independent of patient characteristics and other measures of care. Use of acute antiplatelet therapy was associated with improved survival (1.39; 1.12-1.72) irrespective of other patient and service characteristics. Conclusion: Evidence based treatments, diagnostics, and availability of stroke units were less commonly available in LMICs. Access to stroke units and appropriate use of antiplatelet therapy were associated with improved recovery. Improved access to organised stroke care in LMICs are essential to improve outcomes. Background and Aims: There is a global trend towards evaluating the benefit of medical treatments on the basis of patient-reported outcome measures (PROMs). For intravenous thrombolysis, there is only scarce data on PROMs including health-related quality of life, and no such data is available with respect to IVT in patients with unknown time of symptom onset. WAKE-UP (Efficacy and safety of MRI-based thrombolysis in wakeup stroke: a randomised, double-blind, placebo-controlled trial) aimed at testing the efficacy and safety of MRI-guided IVT in ischemic stroke patients with unknown time of symptom onset. WAKE-UP also aimed at assessing the effect of thrombolysis on PROMs. Method: WAKE-UP was an investigator initiated, European, multicentre, randomized, double-blind, placebo-controlled clinical trial. Patients with unknown time of symptom onset were studied by MRI. Patients with DWI-FLAIR-mismatch were randomised to either treatment with rtPA or placebo. As patient-centric secondary efficacy endpoints, PROMs were obtained 90 days after stroke including quality of life and functional health status assessed by the Euroqol-5D (EQ-5D), and depressive symptoms as assessed by the Beck Depression Inventory (BDI). Results: A total of 503 patients were randomized in the trial. The primary endpoints of the trial will be presented in a separate talk. Here, specifically the effects of IVT on PROMs will be presented. Conclusion: WAKE-UP is the first randomized controlled trial to provide information on the effect of IVT on patient-centric measures in stroke patients with unknown time of symptom. Trial results and their potential impact on clinical practice will be discussed. Background and Aims: Occupational/physical therapy improves poststroke outcomes in a dose-dependent manner. However, many patients receive suboptimal therapy doses for reasons that include cost, availability, and difficulty with travel. This problem is likely to increase with time given the aging population and increased post-stroke survival rates. Telehealth, defined as the delivery of health-related services and information via telecommunication technologies, can potentially address this unmet need. The current study examined the effect of a home-based telerehabilitation program designed to improve motor recovery and patient education in patients with stroke. Method: Using a randomized, assessor-blinded, controlled, non-inferiority clinical trial, a total of 124 participants were enrolled across 11 US centers as part of the NIH StrokeNet clinical trials network. Entry criteria included arm motor deficits (arm motor Fugl-Meyer (FM) score 22-56 /66), stroke onset 4-36 weeks prior, and age !18. Those with significant depression, cognitive impairment, or communication deficits were excluded. Patients were randomized (1:1) to receive 6 weeks of intensive arm motor therapy either (a) in a traditional in-clinic setting or (b) via in-home telerehabilitation (rehabilitation services delivered to the subject's home via an internet-connected computer). Therapy intensity, duration, and frequency were matched across the two groups, with all participants assigned 36 sessions (18 supervised and 18 unsupervised), 80 minutes each (including a 10 minute break), over 6 weeks. The primary endpoint is within-subject change in FM score from the Baseline Visit to 30 Day Follow-Up Visit. Additional measures pertain to stroke education, secondary prevention, behavioral compliance, and patient motivation.
Results: Will-be-presented. Background and Aims: The benefit that endovascular thrombectomy (EVT) offers to stroke patients with large vessel occlusions depends strongly on reperfusion grade as defined by the eTICI (extended Thrombolysis in Cerebral Infarction) scale. We determined the lifetime health and cost consequences of reperfusion for patients, healthcare systems, and society.
Method: A Markov model estimated lifetime quality-adjusted life years (QALY) of EVT-treated patients and associated costs based on eTICI grades. The analysis was performed from a United States health care and societal perspective. Input parameters were based on best evidence, including patient data from the 7-trial HERMES collaboration. Starting age was set to 65 years. Sensitivity analysis was performed using Monte Carlo simulations.
Results: Lifetime QALYs increased for every grade of improved reperfusion ( Figure 1A ). On average, eTICI 3 resulted in 6.50 QALYs over the patients' lifetimes, whereas eTICI 2b (50-66%) yielded 4.80 QALYs. In contrast, healthcare and societal costs per QALY decreased by improved reperfusion ( Figure 1B ). The advantage of achieving eTICI 3 over eTICI 2b (50-66%) reperfusion results in average cost-savings of about $15,000/ QALY and $20,000/QALY per patient incurred by healthcare systems and society.
Conclusion: Every grade of improved reperfusion grants stroke patients additional QALYs and substantially reduces healthcare and societal costs. Procedural strategies to achieve eTICI3 reperfusion should be assessed for safety and feasibility, even when initial reperfusion seems adequate. Background and Aims: The ASPECT Score has become the most widely used score for quantifying signs of infarction. Human readers are known to have a poor performance in recognizing early signs of infarction in CT. For the first time automatic tools for calculating the ASPECT score are available. One of these will be examined in the present work. Method: In a first step, a gold standard was defined by two board certified neuroradiologists in 100 patients suffering from an occlusion in the anterior circulation in knowledge of the complete follow-up imaging. After 6 weeks, the ASPECT Score was again calculated by the two readers independently. In a final step, the CTs were analyzed using a commercially available software (RAPID-CT). Results: Human readers showed a fair agreement with the gold standard (k ¼ 0.574 and k ¼ 0.556). RAPID-CT showed a significant better agreement (k ¼ 0.896). If < 1h had passed between symptom onset and imaging, all readers showed only minimal agreement (Reader 1 & 2: k ¼ 0.187 & k ¼ 0.124; RAPID-CT: k ¼ 0.169). RAPID-CT showed a substantial agreement (k ¼ 0.775) after >1h, which increased to almost perfect agreement (k ¼ 0.923) at the time window >4h. Human readers needed the >4h time interval to achieve similar results (k ¼ 0.828 and k ¼ 0.757). Conclusion: Analysis of the ASPECT score with RAPID-CT is clearly superior to human readers. This is particularly the case in CTs with a small time interval between the onset of symptoms and imaging. Recurrence of chronic subdural hematoma after surgery is frequent. Scans after surgery show often substantial residuals, which may trigger re-operations. However, the benefit of post-surgical imaging for patient outcome remains unknown. Method: We randomly assigned 361 patients with newly diagnosed chronic subdural hematoma, within 48 hours after surgery, to receive either clinical combined with radiological follow-up (CT scans 2 and 30 days after surgery; CT arm; n ¼ 181) or clinical follow-up with scans only in case of neurological deterioration (no-CT arm, n ¼ 180). The primary outcome was assessed after 6 months using the modified Rankin scale (mRS) with categorical scores ranging from 0 (no symptoms) to 6 (death). Results: The proportion of patients who survived without severe disability (mRS 0-3) was 89% in the CT arm and 93% in the no-CT arm (OR 1.4, 95% CI 0.82-3.72, P ¼ 0.15). Twelve patients in the CT arm and 8 patients in the no-CT arm died (P ¼ 0.5). Re-operation for recurrent hematomas was performed in 59 patients in the CT arm and in 39 patients in the no-CT arm (P ¼ 0.055). Complications occured in 26 patients in the CT arm and in 19 patients in the no-CT arm (P ¼ 0.34). The follow-up protocol with CT imaging did not improve the primary outcome; the between-arm difference for mRS was not significant, neither as a categorical (P ¼ 0.79) nor as a numerical variable (P ¼ 0.37). Background and Aims: What factors and their relative importance govern the selection for endovascular therapy (EVT) in real-world evidence are not well known. Method: We conducted an international web-based survey to assess the decision to offer EVT. Ten key patient characteristics were used to construct case scenarios. Respondents saw ten pairs of patient scenarios, randomly generated from the ten patient characteristics and chose which patient (A or B or neither) was best suited for EVT according to their current practice. Hierarchical Bayes' disaggregate discrete choice modelling was used to quantify the relative importance of patients' characteristics in deciding to offer EVT. Results: 603 physicians (mean age 44 (SD 8.5) years, 83.5% men, 53.6% neurologists, 28.7% neuro-interventionists, 13.3% neurosurgeons, 4.7% other), from 38 countries participated. The most influential factor was the extent of ischemic change (ASPECTS/volume of infarct core) (26-28% of the choice). The next important factors were age, premorbid disability, baseline NIHSS score, and site of vessel occlusion (13-15% each). Time from onset was only modestly important (9%). Sex, carotid occlusion, comorbidities, and inconvenience (e.g. EVT at night) (1-3% each) were judged unimportant. Respondents were 17% less likely to favour treating a large M2 occlusion vs. M1, 53% less likely to favour treating low NIHSS score ( 5) vs. !11, and 74% less likely to favour treating low ASPECTS ( 4) patients or core >70cc vs. ASPECTS !8 or core < 30cc. Conclusion: The extent of ischemic changes is a dominant factor in choosing EVT candidates. M2 occlusion is considered an appropriate EVT target. Background and Aims: Physical activity including treadmill-based, aerobic training is a rehabilitative therapy to improve walking abilities and functional outcome after stroke. The effect on activities of daily living of patients in the subacute phase of stroke is unknown [1] . Method: PHYS-Stroke was an investigator initiated, German, multicentre, randomized clinical trial [2] . 200 patients with subacute stroke (day 5-45 after stroke) were recruited from seven rehabilitation clinics, and randomized to receive 25 minutes of either treadmill-based, aerobic physical exercise (study intervention) or relaxation sessions (control intervention) five times per week for four weeks, in addition to standard rehabilitative therapy. Primary outcome was change of gait speed and the Barthel index at three months after stroke (co-primary endpoint). Safety endpoints were recurrent fatal or non-fatal cardiovascular events. Results: A total of 200 patients was randomized in the trial (end of recruitment: April 30th, 2017; Database closed: Nov 10th, 2017), and will be included in the intention-to-treat analysis. Results for primary endpoints after 3 months will be presented, as well safety endpoints. Conclusion: PHYS-Stroke is a clinical trial in the subacute phase adding relevant evidence to the question if aerobic training in subacute stroke improves gait speed and activities of daily life. Moreover, it will determine if the Intervention in the subacute phase after stroke is safe. Trial registration number: ClinicalTrials.gov: NCT01953549 Background and Aims: Effective, time-critical intervention is crucial to mitigate stroke mortality and morbidity but is often hampered by systemic pre-or in-hospital delays. In the era of rapid reperfusion therapy for ischaemic stroke, there is urgent need to improve multi-disciplinary communication to synchronise and coordinate rapid clinical, imaging assessment, and therapeutic decision making across the entire stroke journey from initial emergency medical service (EMS) assessment to inhospital management. We aim to develop an open-source platform that provides a purpose-built, efficient, user-friendly communication system that links EMS, stroke and neuro-interventional teams, aiming to reduce the time from first medical contact to cerebral reperfusion time. Method: N/A Results: The Health Insurance Portability and Accountability Act (HIPAA) compliant platform can be accessed by EMS and hospital staff involved in acute stroke care. When a new stroke alert is lodged by EMS, the application will prompt calculation of relevant clinical scores that aid decision making. An appropriate hospital is then recommended and prenotified of impending stroke patient arrival. is a multifaceted comprehensive post-stroke diseasemanagement-program with the objective of reducing recurrent cardiovascular events and improving quality-of-life (QoL) in stroke and TIA-patients based on an enhanced target level achievement in secondary prevention, systematic detection and treatment of post-stroke complications and patient self-empowerment. Method: STROKE-CARD was designed as a block-randomized (2:1 ratio) pragmatic trial with blinded outcome assessment conducted in two study centres in Austria. It compares intensified (standardized 3-month visit and e-tool for risk factor management and detection of complications) versus usual post-stroke patient care and enrolled 2167 patients with acute ischemic stroke, excluding those with an mRS of 5, or high-risk TIA defined by an ABCD2-Score !3. Results: The mean age of the population (n ¼ 1730) was 68.8 years and 59.6% were males. 18% had a TIA, the median NIHSS of strokes was 3 (IQR ¼ 5), and 23% reported a prior stroke or TIA. 20% of events were attributable to large-artery atherosclerosis, 25% to cardioembolism, and 21% to small vessel disease while 30% were of undetermined and 4% of other determined etiology (TOAST-classification). Median EuropeanQoL-5-Dimensions-Index was 67.5. Patient characteristics were equally distributed in the two study groups. Conclusion: STROKE-CARD will yield evidence on whether a pragmatic post-stroke intervention program is capable of preventing recurrent cardiovascular events and improving QoL. Background and Aims: Stroke patients with reduced arm and hand functions often experience increased dependence in activities of daily living, restricted social participation, and low quality of life. In this context, an intervention combining task-oriented exercises with orthosis in the community rehabilitation unit and home environment is hypothesized to increase perceived goal achievement, repetition, and intensity of exercises. The primary objective of the study is to evaluate the feasibility and clinical usefulness of the program in terms of patient compliance and outcomes improvement. The secondary objective is to compare the effectiveness of the program with or without the use of the orthosis in a randomized controlled trial (RCT). Method: The study will first be carried out in a cohort of 30 stroke patients aged over 18 years regardless of lesion location and temporal evolution. Subsequently, the pilot RCT will include 30 first-time stroke patients in which the experimental group will receive an orthosis for use during the exercises. The intervention will be performed at a rehabilitation unit 3 times/week for 3 weeks and at home for 9 weeks. A comprehensive assessment will be performed at baseline, week 3, and week 12 following intervention. Background and Aims: The SOCRATES trial reported a nonsignificant trend towards greater efficacy of ticagrelor versus aspirin in reducing stroke risk during 90-day treatment, with no increase in major haemorrhage. Dual antiplatelet therapy may be more effective in reducing the high risk of stroke after an acute ischaemic stroke or transient ischemic attack (TIA). Method: The THALES trial (NCT03354429) is a randomised, doubleblind trial in patients with acute ischaemic stroke or TIA. It evaluates whether ticagrelor (180-mg loading dose on day 1, then 90 mg twice daily on days 2-30) is superior to matching placebo among patients also receiving open-label aspirin (300-325 mg on day 1, then 75-100 mg once daily on days 2-30). The primary efficacy outcome is time to the composite end point of stroke or death through 30 days of treatment. The primary safety outcome is time to first severe bleeding event based on the GUSTO definition. Results: Participants are !40 years of age with a non-cardioembolic ischaemic stroke (with a National Institutes of Health Stroke Scale score 5) or high-risk TIA (defined as an ABCD 2 score !6 or with ipsilateral large-vessel stenosis !50%). Participants are randomised within 24 hours of the time last known free of new ischaemic symptoms, and study drug is initiated immediately afterwards. Approximately 13,000 participants will be randomised from about 460 sites worldwide to collect 770 outcome events. Intervention & comparator TASK-CBT: telephone-delivered cognitive behavioural therapy to treat specific feared situations in phobic anxiety and generalized anxiety; online multimedia psychoeducational content and weekly tasks TASK-Relax: web-guided multimedia relaxation exercises, to be practiced daily for at least 5 minutes.
Conclusion

Results: Feasibility Outcomes 1) Recruitment rate per month; 2) % completed electronic consent; 3) time taken for remote eligibility confirmation; 4) completion rate of outcome measures at primary endpoint; 5) intervention fidelity Conclusion: Feasibility of the TASK interventions and streamlined trial design can lead to more efficient large-scale RCTs in the future. Background and Aims: Data from small randomised trials suggest that the modified tissue plasminogen activator tenecteplase at 0.25mg/kg is potentially superior to intravenous alteplase, the only medical treatment currently approved for acute ischaemic stroke, with respect to both safety and efficacy in stroke, in addition to having simpler administration. NOR-TEST found no difference between alteplase and tenecteplase 0.4mg/kg but included predominantly minor strokes and a high proportion of mimics and TIAs. More data are required to establish the true risk-benefit profile compared with alteplase. Method: ATTEST-2 will establish whether tenecteplase is superior to alteplase by undertaking a prospective randomised open blinded endpoint (PROBE) trial in patients eligible for IV thrombolysis based on non-contrast CT imaging. Up to 60 UK centres will recruit 1870 patients. All UK regulatory approvals are in place. The ATTEST-2 study has been adopted onto the NIHR Clinical Research Network Portfolio. Study recruitment is ongoing and will continue until Feb 2020. Results: Primary outcome is the distribution of modified Rankin Scale (mRS) outcomes at day 90, determined by the Rankin Focused Assessment method, analysed by ordinal distribution ("shift") analysis of the of scores in intervention and control groups. Conclusion: An agent with superior risk:benefit ratio to alteplase would potentially extend thrombolytic treatment to a greater proportion of patients than at present and reduce the need for mechanical thrombectomy. This trial will contribute to the optimisation of reperfusion strategies. Trial registration number: ClinicalTrials. Background and Aims: Difficulty in balance maintenance is a particularly common problem for patients with stroke and recovery of balance is an essential component of independence in daily life activities following stroke. Several studies have researched the effectiveness of different physiotherapy interventions previously; however, research with good methodological quality is still needed. This study aimed to investigate the effects of traditional physiotherapy methods and virtual reality interventions on balance in patients with chronic stroke and compare the effectiveness of three different approaches. Method: After the application of inclusion and exclusion criteria participants divided into three groups randomly. The first group receives a standard rehabilitation programme which include trunk stabilization and weight transfer exercises. Participants in video game group receive a 30-minute standard rehabilitation plus 30 minutes of balance training with Wii Fit. Third group receives 30 minutes of standard rehabilitation plus a 30-minute of balance therapy with Biodex balance system (Biodex, Inc, Shirley, NY, USA). All participants receive a total of 16 sessions, 2 times in a week for 8 weeks. We record Berg Balance Scale (BBS), Timed Up and Go Test (TUG), NeuroCom Balance Master System, Stroke Impact Scale Short Form (SIS-16), Fall Efficacy Scale (FES-I), and Physical Activity Enjoyment Scale (PACES) results of patients before and after the rehabilitation programmes. Differences within the groups will be shown using Wilcoxon test and differences between the groups will be indicated by use of Kruskal-Wallis Test. Background and Aims: Embolic strokes of undetermined source (ESUS) represent up to 20% of ischemic strokes and have a high rate of stroke recurrence. This new clinical construct is the basis for two large randomized clinical trials. By available estimates 15-20% ESUS patients will be <50 years and not included in these trials due to the respective trial designs. We seek to determine the clinical characteristics of young-ESUS patients (<50 years) and to determine the rates of new onset atrial fibrillation, stroke recurrence, and death.
Method: Data will be collected from 1000 young-ESUS patients from 100 stroke research centers from different global regions. Patients will be followed up prospectively every 6months up to 18months via telephone Results: We aim to describe clinical, laboratory and imaging characteristics of young-ESUS patients including antithrombotic therapy used and rates of new onset AF, recurrent stroke and death and predictors of these. The recruitment is planned to end in 2018 with follow up ending in 2019. Baseline characteristics of the young-ESUS patients will be presented at this meeting. 3 Saga University Faculty of Medicine, Department of Neurosurgery, Saga, Japan Background and Aims: Sporadic cerebral small vessel disease (SVD)-related lesions on brain CT or MRI seem to be irregularly scattered, but known to be distributed with certain rules according to hypertensive, aging, and amyloid burden. Such mixed irregularities and regularity appears to like a pattern of kaleidoscope. The aims of this study are to explore clinical relevance of the SVD-related lesions on CT/MRI in stroke patients. Methods: The Hypretension, Amyloid, and aGe Associated Kaleidoscopic brain lesions on CT/MRI Undertaken with stroke REgistry (HAGAKURE) is an investigator initiated, prospective, single center, observational study. Eight hundred stroke (i.e. cerebral infarction, TIA, and spontaneous intracerebral hemorrhage [ICH]) patients admitted our division will be enrolled in this study. They will have brain CT and multimodal MRI at baseline and be followed up at least 2 years. Analyses will be separately performed by stroke subtypes (ischemic stroke or ICH). The primary outcome is fetal, or non-fetal cerebro-and cardiovascular events. The secondary outcomes are clinically relevant all cause of death and nursing degree. Funding is from study was supported by a Grant-in-Aid for Scientific Research (C), JSPS KAKENHI (Grant Number 15k10364) which is Japanese governmental research fund. Results: Between September 2012 and August 2016, we enrolled 605 ischemic stroke patients and 196 ICH patients have been enrolled. The study is ongoing through 2019. Conclusions: HAGAKURE study will provide novel risk stratification models for cerebro-and cardiovascular events, death, and care status after stroke by different SVD-related burden at baseline. Background and Aims: Several trials have shown that endovascular treatment (EVT) following intravenous alteplase (IVT) improves outcome of patients with acute ischemic stroke and a proximal intracranial occlusion. A recent meta-analysis of five randomized trials (Hermes collaboration, Lancet 2016), which also included patients with contraindications for IVT, showed that the effect of EVT is not influenced by IVT. The question arises whether IVT is beneficial in patients eligible for EVT. Method: The MR CLEAN-NO IV trial is a multicenter, prospective, randomized, open-label, blinded-endpoint trial, comparing IVT followed by EVT with direct EVT in patients with a confirmed occlusion of the distal intracranial carotid artery, M1 or proximal M2. We aim to include 540 patients. The primary endpoint is the modified Rankin Scale score (mRs) at 90 days. Secondary endpoints include eTICI score, and Barthel score at 90 days. Safety endpoints include symptomatic intracranial hemorrhage and embolization in a new territory on angiography during EVT. The primary effect parameter is the common odds ratio of the mRs, estimated by ordinal logistic regression. We will adjust for age, prestroke mRs, time from onset to randomization, stroke severity and collateral score. We will perform subgroup analyses for occlusion location, collateral score and thrombus perviousness, among others. Results: Currently recruiting patients. Conclusion: The MR CLEAN NO-IV trial will provide robust data on whether IVT is beneficial to patients who are eligible for EVT and who present to a comprehensive stroke center Trial registration number: ISRCTN80619088 AS32-0047 Hence, stroke is an important contributor to reduced diet intake and predisposes patients to a state of malnutrition, which has been shown an independent predictor of mortality and impaired recovery and should thus be avoided. In this study, we aim to obtain comprehensive insights over time in the nutrient levels, nutritional intake and general nutritional status of patients with acute ischemic stroke either with or without dysphagia. Method: This is an observational, single-centre, longitudinal study. A total of 50 subjects with an acute ischemic stroke with NIHSS>4 who are admitted to the stroke unit at Maastricht University Medical Centerþ, the Netherlands will be included in this study, of whom 25 subjects with dysphagia and 25 subjects without dysphagia. By taking blood samples and recording food intake, we will measure the nutritional status and dietary intake during hospital stay as well as at two follow up visits during rehabilitation (6 and 13 weeks after admission). In addition, questionnaires will be used to determine level of independence (Barthel Index and modified Rankin scale) and quality of life (EQ-5D). Results: Expected enrolment of the 1st patient: February 2018 Conclusion: The results from these observations will contribute to insights in the nutritional status of patients after a stroke and will aid improved nutritional management of the patients to prevent nutritional deficiencies. StrokeNet is open to trialists with a proposal within or outside of the network. One innovative feature is the feasibility assessment that includes surveying sites for enthusiasm and availability of patients for trials; and an epidemiological study that applies eligibility criteria to the Greater Cincinnati/Northern Kentucky epidemiologic database. Results: Of the 27 trial proposals investigators have submitted for review, 26% have been approved for funding (3 prevention, 2 acute, and 2 recovery trials). StrokeNet's first trial, DEFUSE 3, was halted early for efficacy. The ARCADIA trial began enrolling in January 2018. MOST and Sleep SMART trials will begin enrolling in mid-2018. In the past year, 26 of 27 StrokeNet fellows presented at a national meeting or published 58 first-author abstracts, 27 first-author manuscripts, and 23 submitted grants. In 2015-16, 92% trainees reported they will be "significantly involved" in research in new positions. Conclusion: NIH StrokeNet has demonstrated the ability to design trials that are scientifically important, innovative, and feasible and to recruit at or ahead of expected rate. It is also a resource for development of stroke researchers. Background and Aims: Cerebral small vessel disease (CSVD) is a common neurological disease and causes about 20% of all strokes and up to 45% of dementia, mood disturbance and gait problems. Small vessels per se cannot be currently visualized in vivo. The diagnosis of CSVD has relied on imaging findings. The leading imaging techniques to visualize brain white matter lesions (WMLs) are brain magnetic resonance imaging (MRI) or computed tomography (CT). (US). With highend ultrasound systems a very high image resolution is achieved. Ultrasound fusion imaging is a novel approach to evaluate brain tissue. Ultrasound is a safe, noninvasive, easily repeatable bedside investigation and offers a reliable opportunity to evaluate structures in real time. Method: Fusion imaging (FI) was conducted with US Esaote -MyLab twice machine. Brain tissue was visualized transcranially using a sector transducer in B-Mode, followed by fusion of imported MR pictures (FLAIR sequence, DICOM format, performed with 1.5 Tesla MRI system, slice thickness 5mm, 10% gap). Electromagnetic (EM) trackingbased fusion imaging was performed. Results: All consecutive patients presenting various degrees of leukoencephalopathy on brain MRI were included after giving written informed consent. Demographic data, relevant cardiovascular comorbidities and medications were documented additionally. Patients with normal brain MRI findings were used as control group. Conclusion: FI was applied on 48 subjects, 36 patients with different grades of WML and 12 controls. The US images were analyzed. The main hypothesis was to evaluate the sensitivity of transcranial B-Mode US to detect different grades of WML using fusion imaging technique. Background and Aims: Many randomised controlled trials (RCT) fail meeting their recruitment goals within time. One possible explanation for the recruitment problem is that people do not want to be part of a study. However little is known about the reasons for individuals acceptance or denials to participate in RCT. EFFECTS (www.effects.se; NCT02683213 is a Swedish academic-initiated, multicentre, randomised, placebo-controlled trial of fluoxetine for stroke recovery. The trial will investigate whether routine administration of fluoxetine (20 mg daily), 6 months after an acute stroke improves patients functional outcome. EFFECTS collaborate with two other studies, FOCUS (UK) and AFFINITY (Australia, New Zealand, Vietnam). Each trial is funded independently and will report its own results. We will use EFFECTS as a host study, and do a Trial within a Study (TWIST) called INTER-EFFECTS, an interview study, the aim is to identify and describe factors contributing to acceptance or denial to participation in a RCT. Method: A qualitative descriptive study with individual interviews with patients who agreed or choose not to participate in EFFECTS. Results: The result could be useful in clinical settings outside the field of stroke and could be applicable to a wide range of RCT studies. The study will add knowledge of the management of RCT. Conclusion: Research about management of clinical trials and how to enhance recruitment to clinical trials is very important and this study can help identify barriers and find solutions to why patients say no to participate in RCT. Trial registration number: The protocol is registered at the Northern Ireland Hub for trials methodology research. Background and Aims: Randomized controlled trial that did evaluate the efficacy of thrombectomy selecting patients based on the presence of a target mismatch (TMM) on multimodal imaging demonstrate a larger therapeutical effect than those who did not. Whether thrombectomy may be limited to the patients among which multimodal imaging is exhibiting a significant amount of penumbra remains controversial.
AS32-
We aim to investigate in a prospective cohort of 220 patients treated by thrombectomy within 6-8 hours onset according to the current imaging recommendations, the relationship between the prevalence of TMM on pretreatment brain imaging with the rate of clinical recovery after thrombectomy. Method: Prospective Multicentric Cohort Study. Consecutive patients eligible to a mechanical thrombectomy according to current recommendation will systematically undergo before treatment multimodal imaging (CTP or MRI) and will be treated according to the current recommendations that do not include the results of penumbral imaging. The processing and the prevalence of a TMM will be assessed after treatment blinded of the success of thrombectomy and the clinical evolution of the patients. TMM prevalence will be defined according to the EXTEND-IA study criteria. Endpoint: Rate of good functional outcome (mRS 0-2 @ 3 months) according to the success of endovascular treatment and the prevalence of TMM (Extend IA definition) on baseline imaging. Background and Aims: Rapid endovascular treatment (EVT) in patients with acute ischemic stroke with confirmed proximal intracranial occlusion has been proven safe and effective. Still, many patients do not recover despite recanalization. Yet, it is unknown whether periprocedural anticoagulant medication in patients treated with EVT can improve clinical outcome. The objective of this study is to assess the effect of acetylsalicylic acid (ASA) and unfractionated heparin, alone, or in combination, in patients who undergo EVT. Method: MR CLEAN-MED is a multicenter, prospective, randomized, open-label, blinded-endpoint trial using a 2x3 factorial design. We planned to enroll 1500 patients with a clinical diagnosis of acute ischemic stroke and confirmed intracranial anterior circulation occlusion, who will undergo EVT with or without prior intravenous thrombolysis according to standard care. Study interventions: IV treatment with ASA (300 mg), low dose unfractionated heparin (loading dose of 5000 IU followed by 500 IU/hour Â 6 hours) and moderate dose unfractionated heparin (loading dose of 5000 IU followed by 1250 IU/hour Â 6 hours). Primary outcome is the score on the modified Rankin Scale 90 days after inclusion in the study. Safety endpoints include the occurrence of symptomatic intracerebral hemorrhage. Results: First patient enrolled on January 22nd, 2018 Conclusion: We hypothesize that despite the potentially increased risk of (symptomatic) intracerebral hemorrhage, periprocedural ASA and unfractionated heparin alone or in combination will improve functional outcome of patients with acute ischemic stroke treated with EVT. Background and Aims: The applicability of prior randomized trials in the management of asymptomatic carotid stenosis to current treatment decisions has been questioned. The NINDS-funded CREST-2 will compare CEA and intensive medical management (IMM) versus IMM alone (n ¼ 1240), and CAS and IMM versus IMM alone (n ¼ 1240) in asymptomatic patients with !70% stenosis. Method: CREST-2 consists of two parallel randomized clinical trials at %120 centers, including collaboration with NINDS StrokeNet. The composite primary outcome is stroke or death during the peri-procedural period or ipsilateral ischemic stroke thereafter up to 4 years. Cognitive status will be assessed periodically through computer-assisted telephone interviews. Centrally directed IMM includes tight control of blood pressure (per current guidelines) and cholesterol (LDL target < 70 mg/dl) as well as lifestyle coaching. Results: As of January 8, 2018, 182 centers have been approved by the Site Selection Committee. Credentialing is ongoing, with 379 approved surgeons and 163 approved interventionists. An additional 184 interventionists have been approved to submit additional cases via the CREST-2 Companion Registry which provides a CMS-reimbursed pathway for full credentialing in CREST-2. 880 patients have been randomized, 429 (48.75%) patients in the endarterectomy trial, and 451 (51.25%) patients in the stent trial. Conclusion: CREST-2 is designed to identify the best approach for asymptomatic carotid stenosis. An update will be provided regarding the numbers of patients randomized, centers certified, as well as surgeons and interventionists fully approved. The CREST-2 Registry will provide the option of CAS while enhancing interventionists' credentials for participation in CREST-2. Background and Aims: Tandem occlusion refers to stroke due to middle cerebral artery (MCA) or distal internal carotid artery (ICA) AND ipsilateral cervical ICA occlusion or near-occlusion. It is found in 12-30% of patients undergoing endovascular thrombectomy (EVT). Optimal acute management of the cervical ICA lesion is uncertain and may include no definitive revascularization versus acute stenting. Practice varies widely across centresand no randomized-control trial (RCT) data exist to guide decision-making. Method: We propose a pragmatic, multicentre PROBE RCT of adult acute stroke patients undergoing EVT which will compare acute stenting for high-grade cervical ICA stenosis/occlusion versus deferred ICA intervention (if indicated). Treatment allocation will occur after confirmation of a tandem occlusion on initial non-invasive vascular imaging (CTA or MRA) but prior to EVT. A standard antiplatelet regimen will be strongly recommended. Anterograde and retrograde ICA stenting will both be permitted. Cross-overs will be allowed in cases of ICA "pseudoocclusions" identified on CTA or MRA, but otherwise cross-overs will be strongly discouraged. Background and Aims: A co-ordinated approach involving >60 international collaborators facilitated the creation of a database on poststroke aphasia (NIHR HS&DR-14/02/22). Individual Participant Data (IPD) meta-analyses will inform our understanding of uncertainties including predictors of recovery, prognosis and highlight interventions amongst targeted trial specific populations optimally suited to investigation within definitive randomized controlled trials. We aimed to create a large, international, research-based IPD archive to support the examination of post-stroke aphasia research uncertainties. Method: We systematically searched for datasets containing IPD on !10 people with aphasia, time post-stroke and aphasia severity (Cochrane Stroke Group Trials, MEDLINE, AMED, CINAHL, Cochrane Library Databases [CDSR, DARE, CENTRAL, HTA], LLBA, EMBASE, and SpeechBITE). Two independent reviewers screened 5256 records, identifying 874 eligible datasets. We invited contributions from the Collaboration of Aphasia Trialists and other aphasia researchers. We double-extracted individual, aphasia, stroke and intervention data. Results: Our database contains 5932 IPD from 174 primary research datasets across 28 countries ( 
Results
We select those cryptogenic strokes who present: not lacunar stroke or different locations at the same time by CT/MRI, absence of extracranial or intracranial aterosclerosis causing !50% luminal stenosis in arteries supplying the area of ischaemia, no major-risk cardioembolic source of embolism, no other specific cause of stroke identified Results: The diagnostic assessment includes: Brain CT or MRI, 12-lead ECG, precordial echocardiography with shunt detection, cardiac monitoring for !24 h with automated rhythm detection, imaging of both the extracranial and intracranial arteries supplying the area of brain ischaemia (catheter, MR, or CT angiography, or cervical duplex plus transcranial doppler ultrasonography). We will select those patients with cryptogenic stroke with at least a finding of the following in the extension study: minor-risk potential cardioembolic sources detected by echocardiography and/or non-atrial fibrillation atrial dysrhythmias.
Conclusion:
The implant is performed prior to discharge. To date, 15 patients have been implanted in 11 months with a detection rate of 20%. We believe that the screening based on such criteria can serve to reduce costs and better select those patients who are candidates. Background and Aims Background: Intravenous thrombolysis (IVT) combined with mechanical thrombectomy (MT) has been proven safe and effective in patients with acute ischemic stroke (AIS) of anterior circulation large vessel occlusion (ACLVO). Despite recanalization, a considerable proportion of patients do not recover. The incidence of symptomatic intracerebral hemorrhage (sICH) was similar between bridging therapy and IVT, suggesting that this complication could not be attributed to the MT, but rather to pre-treatment with IVT. Meanwhile, the incidence of intracranial atherosclerosis stenosis (ICAS) is higher in Asians. It is not clear whether ICAS modifies treatment effect or not. Objective: First, to assess the effect of direct MT compared to bridging therapy in patients with AIS due to an ACLVO. Secondary, to assess treatment effect modification by presence of ICAS. Method: Study design: This is a parallel group, RCT of direct MT versus bridging therapy, using a non-inferiority design. The trial will be executed in collaboration with MRCLEAN NO-IV investigators. Study population: Patients with AIS of ACLVO confirmed by CTA. Initiation of IVT must be feasible within 4.5 hours from symptom onset. Age must be 18 or over and NIHSS 2 or more. Main outcomes: The full distribution of the mRS at 3 months Secondary outcomes: eTICI score on postprocedural DSA, NIHSS at 24 hours and 5-7 days, recanalization on CTA at 24 hours and infarct size on CT at 5-7 days, dichotomous clinical outcome on the mRS and mortality at 90 days. Safety outcomes include rate of sICH. Background and Aims: Endovascular randomized controlled trials (RCTs) have revolutionized management of acute ischemic stroke (AIS) patients with intracranial large vessel occlusion. Despite improved treatment, up to two out of three patients have poor functional outcome. Insilico clinical trials are computer-based simulation of RCTs and are a promising addition and alternative to the expensive RCTs that are or will be set-up to optimize treatment and patient selection. Method: INSIST will model AIS,intra-arterial and intravenous treatment to realize in-silico AIS clinical trials [Figure1] . Libraries of virtual AIS patient populations based on clinical, imaging, histopathological and outcome data of stroke trials including MRCLEAN,MRCLEAN Registry and HERMES (totaling 4500patients) will be developed. In-silico models for thrombosis, thrombolysis, intra-arterial thrombectomy, microvascular perfusion, neurological deterioration after stroke will be integrated to form an in-silico clinical trial. The accuracy of in-silico clinical trials will be demonstrated by comparison with laboratory experiments and reallife RCTs.
Results:
Conclusion: INSIST is an international, inter-disciplinary consortium to develop models for in-silico AIS trials. We hypothesize that in-silico modelling will allow understanding patient-specific (patho) physiology of AIS and interaction with treatment devices at relevant biological levels and treatment outcome. This knowledge can optimize second-and thirdphase clinical trials, improve medical device and drug development, optimize personalized treatment, reduce animal experiments and will support faster implementation of these improvements in clinical practice. INSIST is funded under H2020. Grant:#777072. www.insist-h2020.eu 1 University Hospital Zürich, Neurology, Zürich, Switzerland; 2 University of Twente, Biomedical Signals and Systems, Enschede, The Netherlands; 3 cereneo, Center for Neurology and Rehabilitation, Vitznau, Switzerland Background and Aims: Effective paretic upper limb training poststroke is characterized by intensity and specificity. Therefore, the best training is life itself, but motivation, compensatory function, and effort are often limiting factors. Feedback technology has the potential to encourage self-administered, intensive arm training in the patients' home environment. The present study aims to investigate post-intervention and long-term efficacy of a wrist-worn activity-tracking device providing multimodal feedback on daily arm use in hemiparetic subjects >3 months post-stroke. Method: A prospective, multi-center, assessor-blinded, randomized controlled trial. Sixty-two stroke patients will be randomized in two groups. The experimental group receives a wrist-worn activity-tracking device providing multimodal feedback on daily arm use for 6-weeks. Controls wear an identical device without feedback. Primary outcome is the change in patient-reported amount of daily life arm use from baseline to post-intervention, measured by the Motor Activity Log-14, Amount of Use subscale. Secondary outcomes are change in arm motor function, arm capacity, global disability, patient-reported quality of daily life arm use, and quality of life from baseline to post-intervention and 6-week follow-up, as well as compliance, activity counts, and safety. An intention-to-treat principle will be applied.
Results: Recruitment started in September 2017 and is expected to last until December 2018. Twenty-one patients have been recruited, of whom 14 have completed the study so far and one dropped-out (non-intervention related). There were no related (serious) adverse events. Conclusion: A positive result of this study will underline the importance of feedback on daily life arm use after stroke. Background and Aims: In stroke trials a large variety of different kinds of outcomes are commonly adjudicated. However, there is a lack of evidence on the effect of adjudication on outcomes in stroke trials and if this has any impact on trial conclusions. Therefore, research is needed to understand the role adjudication has in stroke trials. We have developed theAdjudicating Outcomes in Stroke Trials' Collaboration (AOST) with the aim to answer the following question: What are the benefits and costs of adjudicating outcomes in stroke trials? The first work package of AOST is a systematic review which aims to assess how adjudication of the primary outcome in stroke trials impacts on the primary treatment effect estimate. Method: Randomised stroke trials that have a primary outcome which has undergone assessment by both site investigators and adjudicators will be included in this review. To assess the impact of adjudication on each trial, we will calculate the ratio of treatment effects (RTE). The RTE will be calculated as the treatment estimate using the site-assessed primary outcome versus the treatment estimate using the adjudicator-assessed primary outcome. Due to the majority of trials not reporting unadjudicated outcomes, individual patient data or additional trial results are needed from each trial before it can be included. Data Background and Aims: Non-adherence to direct oral anticoagulants (DOACs) remains a matter of concern, especially in the vulnerable population of polymedicated patients with a recent stroke. However, data on electronically monitored adherence and interventions to improve it are scarce. We aim to use electronic monitoring to: (i) accurately measure non-adherence to DOACs, identify predictors and reliable self-reporting strategies and evaluate its association with clinical outcomes, and (ii) assess the adherence-improving effect of an educational and reminderbased intervention in DOAC-treated patients after a recent stroke. Method: This is a monocentric, randomized, crossover, open-label study. Adult polymedicated patients (! 3 drugs including DOAC), hospitalized for an acute ischemic stroke who are self-administering their drugs are eligible for participation. Adherence to DOACs will be monitored electronically throughout the 12-month-long study. After the initial 6-month observational phase following hospital discharge, patients will be counselled and given a multicompartment pillbox for use throughout the subsequent 6-month interventional phase. The pillbox will provide intake reminders (alarms) either during the first or the last 3 months of the interventional phase. Patients will be randomly allocated to alarms-first or alarms-last. A sample of 130 patients provides 90% power to show a 20% improvement with intake alarms in the primary endpoint of nonoptimal timing adherence. Secondary endpoints include other adherence measures, self-reported adherence and clinical outcomes. Results: The study has received ethical approval and enrollment is ongoing. Conclusion: This study will investigate aspects of non-adherence and the effect of an adherence-improving intervention in the previously unexplored population of DOAC-treated patients with a recent stroke using electronic monitoring. Background and Aims: Post-stroke hyperglycaemia (PSH) occurs in up to 50% of patients presenting with acute ischaemic stroke (AIS). It reduces the efficacy of thrombolysis, increases infarct size, and worsens clinical outcomes. Insulin-based therapies have generally not been beneficial in treating PSH as they are difficult to implement, may cause hypoglycaemia, possibly increase mortality and worse clinical outcomes. Exenatide may be a safer, simple, and more effective alternative to insulin in AIS. Method: TEXAIS is a 3-year, Phase 2, multi-centre, prospective, randomised, open label, blinded end-point (PROBE) trial comparing Exenatide to Standard of Care. It aims to recruit 528 patients with a primary end point of major neurological improvement 1 at 7 days defined as a !8-point improvement in NIHSS score, or NIHSS 0-1. Secondary outcomes of hyper-and hypoglycaemia at 5 days and NIHSS and mRS at 90 days will be measured. The treatment arm will receive Exenatide 5mg subcutaneously twice daily. The control arm will receive standard stroke unit care. Continuous glucose monitors will track the dynamic variability of glucose. Results: Recruitment in TEXAIS has commenced with 10 patients enrolled to date. Conclusion: TEXAIS aims to show that Exenatide is safe and effective in the treatment of PSH. It has been designed to be highly generalisable with an ability to enroll a large percentage of patients with AIS, regardless of admission blood glucose level, diabetes status, or stroke severity, with very low risk of hypoglycaemia. Background and Aims: The Dutch CBO guideline for stroke recommends transthoracic echocardiography (TTE) in all patients with ischemic stroke or TIA of undetermined cause. The scientific basis of this recommendation, however, is debatable. We aim to develop a prediction model to select patients who are most likely to have TTE abnormalities leading to alteration in management, improving the therapeutic yield of TTE in these patients. Method: Seven Dutch hospitals will participate in this multicenter crosssectional study, which will run for a period of three years. The population will consist of 1300 patients with TIA or ischemic stroke of undetermined cause after standard diagnostic evaluation. The primary outcome measure will be the proportion of patients with TTE findings resulting in management changes. A prediction model will be developed based on clinical findings and additional investigations to predict the primary study outcome in a derivation cohort consisting of 60% of the study population. Model performance will be externally validated in the remaining 40%. A cost-effectiveness analysis of the following strategies will be determined : 1) TTE in all patients; 2) TTE only in selected patients with an increased likelihood of therapeutically relevant TTE findings; 3) no TTE. A Markov model will be used to estimate life-long health effects and costs. Results: Not available yet. Conclusion: It is unclear whether routine use of TTE is useful in patients with TIA or ischemic stroke of undetermined cause. This study will provide data to identify the optimal and cost-effective approach of TTE in patients with TIA or ischemic stroke. Background and Aims: Recent studies have suggested that administration of glyceryl trinitrate (GTN) via a transdermal patch in the first hours after stroke onset increases the chance of a favourable outcome, possibly through an increase in intracranial collateral blood flow and a reduction in blood pressure. MR ASAP aims to investigate the effect of transdermal GTN, started within 3 hours of stroke onset in the prehospital setting, on functional outcome at 90 days in patients with acute ischaemic stroke or intracerebral haemorrhage. Method: Phase III, multicentre, randomised, open-label clinical trial with blinded endpoint assessment (PROBE). 1400 patients with suspected stroke and a systolic blood pressure ! 140 mmHg will be randomly allocated to transdermal GTN (5 mg/day), administered by paramedics in the prehospital setting within 3 hours of stroke onset and continued for 24 hours, or to standard care. This trial will be conducted in the Netherlands and will use a deferred informed consent procedure. The primary outcome is functional outcome, assessed with the modified Rankin Scale at 90 days. Results: Ethics approval is obtained and enrolment will start April 3rd 2018. Conclusion: MR ASAP will assess whether very early administration of GTN improves outcome after stroke in a setting where rates of intravenous thrombolysis and endovascular treatment for acute ischaemic stroke are high. The deferred consent procedure facilitates prompt GTN treatment and will prevent delay to revascularisation therapies. If early transdermal GTN treatment proves to be effective, this low-cost treatment can be readily implemented into daily clinical practice. Background and Aims: Unilateral Spatial Neglect (USN) is a cognitive impairment of awareness of one side. This study investigates a brief intervention (Prism Adaptation Training (PAT)) within UK NHS occupational therapy (OT) to determine the feasibility and acceptability of PAT and of conducting a larger randomised controlled trial (RCT). The ultimate purpose is to enable people with USN to better engage in OT to maximise independence in activities of daily living. Method: Mixed methods design: pragmatic, feasibility, multi-centre, stratified RCT with nested process evaluation and proof of concept exploration. RCT Participants: $60 adult stroke survivors, 1-4wks post-admission with neglect, recruited from 6 sites; $40 carers. Treatment condition is OTwith PAT; control condition is OTwithout PAT, delivered 5 times weekly for 3 weeks. Randomisation: random allocation into one of two study arms in a 3:1 (treatment: control) ratio, stratified by site. Researchers will be blind to group allocation. Proof of concept: we will video the first session to examine the immediate effect of PAT on OT engagement. Feasibility outcomes: recruitment, fidelity, acceptability, attrition. Participant outcomes: standardised neglect tests and extended activities of daily living. Process evaluation: 12 patients and 12 therapists will undergo qualitative interviews (after outcome assessments) to help us understand their experiences of PAT, including acceptability of PAT, plus the best setting for recruitment and application of PAT. Background and Aims: For patients with prior intracerebral haemorrhage (ICH), little is known about benefits and harms of using antithrombotic drugs (antiplatelets or anticoagulants) for prevention of ischaemic events. Guidelines variably endorse both starting and avoiding such treatment, and clinical practice is varying. We wish to examine the safety and efficacy of this treatment principle. Method: STATICH is an investigator-led, multicenter, randomised-controlled, open, blinded end-point clinical trial of antithrombotic treatment for prevention of ischaemic events in patients with spontaneous, primary ICH who have indication for antithrombotic treatment. Patients with an indication for antiplatelet drugs will be randomised to antiplatelet drugs vs. no antithrombotic drugs. Patients with atrial fibrillation who have indication for anticoagulation will be randomised to anticoagulants vs. no anticoagulants (antiplatelet drugs are allowed). Patients will be followed for two years and contacted again at 5 and 10 years. The primary outcome variable is recurrent symptomatic ICH. Secondary variables include other intra-and extracranial haemorrhage, ischaemic events, death, and functional and cognitive outcome. In an MRI sub-study we will examine the association between MRI findings (e.g. cerebral microbleeds) and effects of antithrombotic treatment on the risk of recurrent ICH. Results: Patient enrolment will start in 2018 and last until 2020. Target recruitment is 500 patients from hospitals in Norway, Sweden and Denmark. Conclusion: We will determine:
1. the effect of antithrombotic drugs on the risk of recurrent ICH. Background and Aims: Patients with symptomatic intracranial atherosclerotic stenosis (ICAS) are at high risk of recurrent stroke despite of medical treatment. We aimed to investigate whether hemodynamic features of symptomatic ICAS might correlate with the risk of stroke relapse, using a computational fluid dynamics (CFD) model. Method: This is a longitudinal observational study. We recruited patients with acute ischemic stroke or transient ischemic attack attributed to !50% ICAS confirmed in CT angiography (CTA) from 3 teaching hospitals. A CFD model was built in each case based on CTA source images, to reveal and quantify the hemodynamic features of the qualifying ICAS lesion. All patients were followed up for 1 year. The primary outcome is recurrent ischemic stroke within the same territory within 1 year. We shall analyze the associations between CFD model-based hemodynamic features of ICAS and the primary outcome, independent of vascular risk factors and medications. Results: Patient recruitment and follow-up, and CFD modeling procedures have been completed. Overall, 301 patients were recruited; 244 patients (mean age 60.5 years; 63.5% males) with a successfully built CFD model and complete follow-up information were included in analysis. The median intracranial stenosis was 66%. The median post-and pre-stenotic pressure ratio across the ICAS lesions was 0.94. Eighteen (7.4%) patients had a primary outcome. Assessment of other hemodynamic features of ICAS lesions and statistical analyses are underway. Conclusion: Findings of the current study may shed light on the mechanisms of refractory stroke in patients with symptomatic ICAS and inform secondary prevention of these patients. Trial registration number: N/A Background and Aims: The aim of this trial is to investigate the effect of a multimodal intervention consisting of a rigorous peer-to-peer-review of the stroke team algorithm, applying principles of crew resource management (CRM) and up to three sessions of a stroke team simulation training with a debriefing focusing on team communication in a controlled prospective pretest-posttest design at seven tertiary care stroke centers in Germany. Method: In the pretest period, the participating seven centers (tertiary care university hospitals with thrombectomy capacity 24/7/365) record the data of all consecutive patients receiving thrombolysis and/or thrombectomy of all direct-to-center patients during a 3-month period. During the intervention phase, leading employees of different professional backgrounds will be invited to a joint "training of multipliers" seminar. After reviewing and adapting current workflow improvements, up to three stroke team simulation trainings are held at the participating centers and teaching materials will be provided with the aim of permanently starting up regular stroke team simulation. In the posttest period process times are recorded again for three months. Primary outcome measure is the median "door-to-needle" time, which will be verified by independent source data verification. Secondary outcome measures include the median thrombectomy process times of patients receiving thrombectomy and hemorrhagic transformation in the control imaging as a safety endpoint. Staff satisfaction improvement is assessed by means of a pre-designed questionnaire. https://clinicaltrials. gov/ct2/show/NCT03228251. Results: The recruitment of this study is ongoing. Preliminary results of the observation phase I will be shown at the ESOC. Final results are expected in december 2018. Conclusion: n/a Trial registration number: NCT03228251 Background and Aims: Time is the most crucial factor for the clinical benefit of intravenous thrombolysis (IVT) and endovascular thrombectomy (EVT). The delay from notification at the Emergency Medical Services (EMS) dispatch office until initiation of acute treatment depends on logistics and collaboration between various caregivers in this trajectory (identified as 'total system delay' [TSD]). We aim to evaluate whether real-time audio-visual feedback to caregivers will reduce treatment delays. Method: The 'A Reduction in Time with Electronic Monitoring In Stroke' (ARTEMIS) trial is a multiregional, multicenter, randomized open end-point trial. We will include consecutive, adult patients that are considered potentially eligible for IVT and/or EVT by the EMS dispatch office or paramedic on-site in three regions in the Netherlands. Real-time audio-visual feedback on actual TSD will be provided to caregivers through an automatic tracking system, using patient-specific Bluetooth wristbands and pre-mounted tablets throughout the entire trajectory. Randomization of real-time audio-visual feedback will be per patient. By including 75 EVT-and 225 IVT-patients in each arm (real-time audio-visual feedback vs. regular care), we will be able to demonstrate a 20-minute reduction on TSD to EVT and a 10-minute reduction on TSD to IVT. Results: The study is ongoing in Leiden region since February 2018, with current inclusion number of 6 patients. It is expected that Amsterdam region will start in April 2018 and Twente region in May 2018. The study is ongoing through 2020. Conclusion: The ARTEMIS trial will investigate whether real-time audiovisual feedback to caregivers within the acute stroke trajectory will reduce TSD to IVT and/or EVT. Background and Aims: Whether pre-treatment with intravenous thrombolysis (IVT) prior to mechanical thrombectomy (MT) with stent retrievers is beneficial has become a matter of debate. In a patient-level pooled analysis of five randomized controlled studies (HERMES collaboration) the treatment effect size of MT did not differ between patients receiving IVT and those treated with MT alone. SWIFT DIRECT aims to determine, whether direct MT in patients with proximal vessel occlusion in the anterior circulation is non-inferior to IVT and MT. Method: The international, multicentre, randomised-controlled, twoarm, open label, blinded endpoint (PROBE) trial SWIFT DIRECT will randomize 404 patients into the experimental arm (direct MT; 202) or control arm (bridging thrombolysis; 202). The trial will only be performed in patients with immediate access to MT. Main inclusion criteria are signed informed consent, age >18 and < 86 years, confirmed ischaemic stroke, NIHSS !8 and < 30 and eligibility for IVT and MT. The primary outcome is functional independence (mRS) 2 at 90 days. Main secondary outcomes are mortality, change in NIHSS score post randomization, time to reperfusion (TICI !2b) and quality of life. Background and Aims: When to start anticoagulation in ischaemic stroke patients with atrial fibrillation (AF) is a relevant unanswered question. Direct oral anticoagulants (DOACs) are at least as effective as Vitamin K antagonists in reducing stroke and systemic embolism and have a lower risk of intracranial haemorrhage. The ELAN trial will determine the net benefit of early versus late initiation of DOACs in patients with acute ischaemic stroke related to AF with respect to stroke size. Method: This international, multicentre, randomised-controlled, twoarm trial will randomise 2'000 patients into the experimental arm (early treatment; 1'000) or control arm (late treatment, 1'000). The time of DOAC initiation will vary depending on stroke size (i.e., minor, moderate, or major). Main inclusion criteria are signed informed consent, age >18 years, confirmed ischaemic stroke and AF and agreement of treating physician to prescribe DOACs. The primary outcome is a composite of major bleeding, recurrent ischaemic stroke, systemic embolism and/or vascular death at 30 AE 3 days after randomisation. Background: The source of embolic stroke, in thrombotic embolism, is of unknown origin in 30-40% of cases. Fortunately, Mechanical thrombectomy provide a direct method to retrieve the stroke-incriminated clots from stroke patients for possibility of exo-autopsy analysis. Aim: collecting stroke-incriminated clots from definite known etiological sources, could build a matchable markers database (MMD) to identify the source of cryptogenic embolism in the near-future. Identification of that markers is done by novel RNA sequencing technology to identify the clot composition in direct way. Method: This is a prospective double blinded controlled investigational REB-approved study of acute LVO ischemic stroke in patients receiving mechanical thrombectomy at a multiple centers. Immediately after thrombi will be retrieved by mechanical thrombectomy, they will be placed in RNA stabilization and storage solution (RNAlater). Each sample will be extracted for total RNA by the one approved regional university's Human Genomics lab using a standard protocol. NanoDrop Microvolume Spectrophotometers and Fluorometer will be used for RNA quantification. Thrombi weight will be recorded among other clinical data,procedural data, and macroscopic clot morphology. Clots analysis will be divided into 2 groups where Group A : include clots with definite stroke etiology and submitted to the RNA analysis in blinded coded label. Group B: include all clots with unknown stroke etiology and submitted to RNA analysis in cryptogenic label. Results: the trial will be conducted from 2018 to 2022. All analysis will be re-audited in central genome analysis lab of Alexandria University. Background and Aims: Current guidelines do not provide evidencebased recommendations on optimal time-point to start non-vitamin K antagonist oral anticoagulants (NOACs) after ischemic stroke in patients with atrial fibrillation (AF). The TIMING study aims to establish the efficacy and safety of early vs. delayed initiation of NOACs in these patients. Method: The TIMING study is a national, investigator led, registrybased, multicentre, open-label, randomised controlled study. The Swedish Stroke Register is used for enrolment, randomisation and follow-up of 3000 patients, who are randomized (1:1) within 72 hours from stroke onset to either early ( 4 days) or delayed (5-10 days) start of NOAC. Primary outcome is the composite of recurrent ischemic stroke, symptomatic intracerebral haemorrhage, or all-cause mortality within 90 days after randomisation. In an optional biomarker substudy, blood samples are collected from approximately half of the patients for central analysis of cardiovascular biomarkers after study completion. Results: Enrolment of patients started in April 2017 and is anticipated to continue throughout 2019. Recruitment of stroke units is still ongoing. The independent Data Monitoring and Safety Committee oversaw study conduct in December 2017 without any recommendations of study changes. As of March 28, 2018, the 28 participating stroke units had included 129 patients. Conclusion: The TIMING study addresses the ongoing clinical dilemma of when to start NOAC after ischemic stroke in patients with AF. By the inclusion of a randomisation module within the Swedish Stroke Register, the advantages of a prospective randomised study design is combined with the strengths of a comprehensive clinical quality register. Trial registration number: ClinicalTrials.gov Identifier: NCT02961348.
Conclusion
Background and Aims: One of today's challenges in stroke medicine is to further decrease event-to-treatment-time. Our aim is to optimize triage of presumed stroke patients already before arrival at the hospital using a video link connecting ambulance and stroke specialist. We hypothesize that door-to-needle-/-groin-puncture-time can be decreased by evaluating potential stroke patients via video as ER admission can be bypassed and patients with a suspected stroke can proceed directly to imaging. Method: In this observational, prospective cohort-study 120 subjects will be analyzed to investigate feasibility of our local telestroke-concept. In the first two phases ten healthy subjects and ten stroke patients were examined and recorded in order to establish our protocol, using the RACE-Score (items: facial palsy, arm/leg motor function, head/gaze deviation, aphasia/agnosia). Consecutively 100 presumed stroke patients will be analyzed in acute settings as emergency department or ambulance and a decision is simulated: Either admission directly to imaging, or first to the ER for further clinical examination. Results will be independently validated and compared to on-site-examination results. Ultimately RACE-Scores will be analyzed to define a cutoff-score for subsequent studies. Technically a VIDYO V R -connection is established between a mobile device (I-Phone 7S V R ) on-site and a personal computer, run by the stroke professional off site. A short briefing and the neurol.examination are recorded on a protected server. Stroke is defined as a focal neurological deficit with acute onset and presence of a corresponding vessel occlusion in angiography, signs of bleeding or early ischemic injury on CT, or corresponding lesion on diffusion weighted MRI (DWI). Results: N/A Conclusion: N/A Trial registration number: NCT03370094 Background and Aims: The optimal duration and timing of cardiac rhythm monitoring after cryptogenic stroke is unknown. Identification of reliable biomarkers indicating AF will be valuable in the selection of patients for prolonged cardiac rhythm monitoring. The purpose of the study is to assess the incidence of AF detection using implantable cardiac monitors (Reveal LINQ V R ) in patients with cryptogenic stroke or TIA and to identify biomarkers that can be used as predictors of incident AF. Method: Our study is a multi-center prospective observational study of the occurrence of AF in cryptogenic stroke / TIA patients with implantable cardiac monitors for 12 months. Blood samples measuring biomarkers are taken in the acute phase and at 12 month s follow-up. Estimated number of patients to be included in the study is 500. Results: By March 2018, the total number of patients included in 11 out of 18 participating centres, is 76. Out of 76 included patients, AF or atrial flutter has been detected in 18 patients, resulting in detection rate of 23,7 %. The pilot study has identified biomarkers that seem to be useful for the detection of AF in cryptogenic stroke / TIA.
Conclusion: Updated interim analysis of included patients will be presented as well as new results from extended analyses of biomarkers. Trial registration number: NCT02937077 Conclusion: Adult-onset MERS is an entity with a broad clinicoradiological spectrum because of the various diseases and conditions. There are similar characteristics between MERS in adults and children, also some differences Background and Aims: Ovarian hyperstimulation syndrome (OHSS) is a serious complication that occurs after the ovarian-induction treatment. Acute cerebrovascular accident is one of the most dangerous manifestations of the syndrome. However, the characteristics of stroke resulting from OHSS have so far not been well summarised in any study. Method: We reported 2 cases of acute cerebrovascular accidents secondary to OHSS. And then we performed a literature search for reports on this type of stroke, and summarised their characteristics Results: Thirty-six published cases of this type of stroke were reviewed. Thirty two out of 36 (88.9%) of the women were 35 years old or younger. Stroke in 28 out of 36 (77.8%) of these cases was caused by arterial thrombosis. In 17 out of 28 cases, the involved cerebral vascular branches were mainly middle cerebral artery (MCA) and internal carotid artery (ICA). The acute cerebrovascular accidents happened 7 and 9.25 days after embryo transplantation or 8 and 8.33 days after last human chorionic gonadotropin treatment respectively. The prognosis of patients was relatively good after anticoagulation and some supportive treatments. Conclusion: The MCA and ICA are easily involved in stroke resulting from OHSS. The young age may be a risk factor for developing stroke secondary to OHSS. Once thromboembolism develops, administering appropriate therapy is crucial. Background and Aims: Speech recovery is one of the commonly overlooked parameters that have a significant impact on patient's quality of life, which ultimately affects recovery and functioning after stroke. Unfortunately, there is a lack of data on the effectiveness of available pharmacologic interventions on speech recovery after stroke. The aim of this pilot study is to assess the effect of regularly prescribed secondary prevention drugs on speech recovery after stroke. Method: Stroke patients referring to the speech rehabilitation clinic at King Abdullah University Hospital (KAUH) were recruited into the study after getting their informed consent. Patient's baseline language and speech in addition to their current medications were documented. Background and Aims: Subcortical white matter stroke constitutes up to 30% of all stroke subtypes, occurs initially as silent infarcts in the white matter (WM), and contributes significantly to the development of vascular dementia. Activated protein C (APC) is a plasma serine protease that is capable of antithrombotic, anti-inflammatory, anti-apoptotic, and cellsignaling activities. 3K3A-APC, a recombinant variant of APC with reduced (>90%) anticoagulant activity, engineered to reduce APC-associated bleeding risk while retaining normal cell-signaling activity, has shown benefits in preclinical models of ischemic stroke with large infarcts involving large brain arteries and gray matter. A multicenter Phase 2 randomized clinical trial has enrolled 110 patients to assess the safety, pharmacokinetics, and efficacy of human recombinant 3K3A-APC in acute ischemic stroke patients following endovascular thrombolysis (NCT02222714). The aim of this study was to investigate the effect of 3K3A-APC on white matter stroke Method: In the current study, a subcortical WM stroke model was induced by vasoconstrictor N5-(1-iminoethyl)-L-ornithine, dihydrochloride (L-Nio). L-Nio (Calbiochem) was injected into subcortical WM of the anterior cingulum (AC) of the corticolimbic circuit or the subcortical white matter ventral to the mouse forelimb motor cortex. Mice received 0.2 mg/kg intravenously of recombinant murine 3K3A-APC or saline at 4, 24, 48 and 72 h after stroke.
Results:
The results indicate that 3K3A-APC significantly reduces infarct volume, protects blood brain barrier damage 3 days after stroke, and improves remote memory function 4 weeks after stroke, compared to vehicle.
Conclusion: These results demonstrate that 3K3A-APC might be an effective treatment for white matter stroke. Background and Aims: Carotid-femoral pulse wave velocity (cf-PWV) is a surrogate measure of aortic stiffness and predictor of cardiovascular morbidity and mortality. Previously, we demonstrated the significance of cf-PWV as a dichotomous variable in predicting late outcome after ischemic stroke based on a 99-subject group analysis. In this study, we assessed the association between cf-PWV as a continuous variable and late outcome in a nearly doubled group of patients. Method: We recruited 174 subjects admitted to the Department of Adult Neurology, Medical University of Gda nsk, Poland, within 24 hours from the ischemic stroke. In the final analysis, we used the following data: National Institutes of Health stroke scale (NIHSS) score evaluated on day 1; cf-PWV and blood pressure, on day 7; and modified Rankin scale (mRS) score, 3 months after stroke. mRS of 0 or 1 was defined as a favourable late outcome. cf-PWV (as a continuous variable) was compared between favourable and unfavourable outcome groups. The multivariate logistic regression analysis of the data included the possible main confounders. Results: The median age was 63.1 (interquartile range [IQR], 56.6-70.1); median NIHSS, 6.5 (IQR, 3-8) . In univariate analysis, cf-PWV was significantly lower in the favourable outcome group (9.8 vs. 11.0m/s, p ¼ 0.01). In multivariate logistic regression, after adjustment for age, sex, mean blood pressure, NIHSS, and tissue plasminogen activator administration (tPA), cf-PWV remained significantly lower in the same group ( Background and Aims: The risk for cerebrovascular late effects among childhood cancer survivors is considerable. According to recent studies it is not clear which marker could be reliable for the screening of cerebrovascular diseases among the long-term survivors of childhood cancer. The purpose of this study is to analyse arterial stiffness and intima media thickness as possible early markers of later occurring stroke. Method: Twenty-three patients, treated for HD in childhood, were included. They had received radiation therapy to the neck with 20-65 (med.30) Gy. Twenty-six healthy controls, matched in age, sex, BMI, arterial hypertension, smoking history and total cholesterol levels were compared. High-resolution colour-coded duplex sonography and power Doppler sonography of the carotid arteries were performed and intima -media thickness, number and quality of plaques were measured. Arterial stiffness indices were calculated. Results: Plaque deposits and/or arterial wall calcinations were found in 24 out of 43 (55.8 %) vessels in cancer survivors group and 0 out of 52 vessels in the group of healthy controls (p < 0.01). We found significant group differences for all the stiffness parameters we used (P < 0.05), but there was no difference in intima-media thickness between cases and controls (p ¼ 0.92). In a multivariate model, carotid pulse wave velocity was positively associated with smoking.
Conclusion:
The arterial stiffness has appeared as a possible surrogate marker for stroke in long-term survivors of childhood cancer. Smoking habit might have an additional negative influence on vascular aging in the group of patients after neck radiotherapy. To identify and evaluate existing literature concerning the effects of computer based cognitive rehabilitation (CBCR) on visuospatial neglect after four types of acquired brain injury. Method: Databases Medline, EMBASE, PsycINFO, and CINAHL were searched with search strings developed for this review. Authors of relevant literature were contacted to detect supplementary unpublished data or articles not found by searching databases.
Selection criteria: Initial inclusion criteria were: Studies investigating effects of CBCR on visuospatial neglect in one of four types of acquired brain injury, studies in which it was possible to judge the effect of CBCR compared to a passive or active control group, and studies that were both randomized and controlled. No studies met the initial inclusion criteria. Instead, studies were selected for a discussion of the limitations of the current literature if they included CBCR training in rehabilitation of visuospatial neglect following acquired brain injury, but failed to meet certain agreed original inclusion criteria. Results: No studies were identified that investigated the effects of CBCR in the rehabilitation of visuospatial neglect after acquired brain injury compared to a control group in a randomized, controlled setting. Conclusion: Based on existing literature, it is not possible to conclude on the effects of CBCR in the rehabilitation of visuospatial neglect after acquired brain injury. Future studies need to be controlled and properly randomized, and compare CBCR to both passive and active control groups to clarify its effectiveness. Background and Aims: In recent years more and more attention of researchers attracted neurostimulator effect of pulsed magnetic fields, such as transcranial magnetic stimulation. There is information about the increase of the functional activity of clock mechanisms of the brain under the influence of short-term local alternating magnetic field. The aim: To study the effect of ion-reflex impulsive magnetic electrophoresis EGb 761 V R on bioelectric activity of the brain of patients with ischemic stroke (IS) in the early recovery period. Method: There was study of bioelectrical activity of the cerebral cortex of 35 patients with IS in the early recovery period, aged 26 to 76 years with the help of electroencephalography recording. The study was carried out three times: before, after the first magnetic electrophoresis session, third record -at the end of 5 sessions. Results: In the dynamics of treatment, signs of regression of disorganization of brain bioelectric activity in the form of a redistribution of frequency components toward the alpha-rhythm (35.7%) are noted with a decrease in slow-wave activity (delta up to 15.8%, theta to 24.2%). Positive shifts in the delta range (mainly in the fronto-temporal lobes) have been noted as a decrease in the coherence coefficient (F3-F4 from 0.45 to 0.39, T5-T6 À0.43 to 0.37). Patients noted improvement in general well-being, improvement of memory, attention, and synchronization of circadian rhythms of sleep. Conclusion: The study showed a positive effect of ion-reflex impulse magnetic electrophoresis on the functional state of the brain, more successful neurorehabilitation of patients with IS in the early recovery period. Trial registration number: N/A Background and Aims: Venous Thrombo Embolism (VTE) prophylaxis using Intermittient Pneumatic Compression device (IPC) is not possible in all stroke patients, we changed our pathway to include the Neuromuscular Electrical Stimumaltion (geko TM ) device as an alternative for patients with acute stroke who had contradictions/not tolerate IPC. The aim of this audit was to assess the acceptability of this new practice for patients and staff and its impact on VTE. Method: The audit included 455 patients admitted to the Acute Stroke Unit at Royal Stoke University Hospital RSUH) All stroke patients who are immobile are given VTE prophylaxis, unless they are paliated, refusing the intervention, or fully anticoagulated. Every patient is reviewed daily on a nurse-led VTE ward round to monitor compliance with VTE prophylaxis. Results: In total 6/455 (1.3%) patients developed symptomatic VTE (3 DVTs and 3 PEs) within 90 days. Of these, 4 patients (1.6%) were prescribed IPC, 1 patient (1.3%) was prescribed the geko TM device as a secondary intervention and 1 patient (1.5%) patient was prescribed anticoagulation. There was no DVT or PE in patients treated with the geko TM device as the primary VTE prophylaxis. Conclusion: This audit shows a low incidence 1.3% of symptomatic VTE in a high risk population of all immobile stroke patients during the audit period. 36% had contraindications to or did not tolerate IPC. The number of patients treated with geko TM in this project was 35.6%, but, while limited, our data suggests that the geko TM device may be as effective as IPC in our patient cohort Trial registration number: N/A
